相关实验视频

Updated: Jan 10, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

通过过度表达T细胞因子1来重塑CAR-T细胞

Hao Yao^1,2, Yuntian Ding^1,2,3, Qian Chen^1,2

¹Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.

Frontiers in immunology

|November 26, 2025

概括

在仿真抗原受体 (CAR) T 细胞中恢复 T 细胞因子1 (TCF-1) 增强了它们的持久性和抗瘤活性. 这种TCF-1调节改善了CAR-T细胞的寿命和血液恶性瘤的疗效.

科学领域:

免疫学免疫学免疫学
细胞生物学细胞生物学
癌症治疗癌症治疗

背景情况:

化学抗原受体 (CAR) T细胞疗法在血液恶性瘤中显示出前景.
不够的CAR-T细胞持久性限制了治疗疗效.
T细胞因子1 (TCF-1) 对于T细胞的记忆和自我更新至关重要,但在CAR-T细胞中表达不足.

研究的目的:

调查恢复TCF-1表达是否可以改善CAR-T细胞的持久性和功能.
评估TCF-1过度表达对CAR-T细胞表型,增殖和抗瘤活性的影响.

主要方法:

人类T细胞是用CAR载体进行工程的,有或没有TCF-1.
分析包括流细胞测量,细胞因子分析,杀死试验和RNA测序.
机器学习被用于高维的免疫表型.

主要成果:

过度表达TCF-1减少了细胞亡和激活标志物,增加了天真和干细胞类子集.
修改后的CAR-T细胞显示增强的增殖能力,持续的细胞毒性和改善的持久性.
转录组分析揭示了细胞周期和代谢途径的丰富,支持长寿.

结论:

过度表达TCF-1增强了CAR-T细胞的持久性和抗瘤功效,通过赋予对亡的抵抗力和促进较少差异化的状态.
调节TCF-1是一种潜在的策略,可以提高CAR-T细胞治疗复发性/耐药性血液癌症的耐久性和安全性.

关键词:

卡尔 (化学抗原受体) T 细胞 CRS - 细胞因子释放综合征 T细胞的持久性T细胞持久性这就是TCF (T细胞因子).免疫疗法免疫疗法

更多相关视频

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

相关概念视频

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...